ReviewTherapeutic advances in medical oncology2017
Neoadjuvant chemotherapy in soft tissue sarcomas: latest evidence and clinical implications.
Review in Therapeutic advances in medical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 138 citations in OpenAlex.
- First-in-Human Study of CEB-01: Novel Loco-Regional SN-38-Releasing Membrane to Prevent Local Recurrence in Retroperitoneal Sarcomas.Annals of surgical oncology · 2026Trial
- Intratumoral oncolytic virus OH2 injection in patients with locally advanced or metastatic sarcoma: a phase 1/2 trial.Journal for immunotherapy of cancer · 2025Trial
- Neoadjuvant Chemotherapy in Retroperitoneal Sarcoma: A National Cohort Study.Annals of surgical oncology · 2023Trial
- Trial
- Trial
- Primary thoracic synovial sarcoma in a 45-year-old male: A case report and literature review.Oncology letters · 2026Article
- High-throughput screening identifies the activity of histone deacetylase inhibitors in patient-derived models of soft tissue sarcoma.Cancer biology & therapy · 2025Article
- A case report of giant retroperitoneal liposarcoma.Medicine · 2025Article
- Retroperitoneal multiple giant liposarcoma: a case report.Frontiers in surgery · 2025Article
- Thirty Days Outcomes of Limb Salvage Surgery in Pediatric Patients Treated at a Tertiary Care Hospital.Cureus · 2024Article
- Opportunities and Challenges in Soft Tissue Sarcoma Risk Stratification in the Era of Personalised Medicine.Current treatment options in oncology · 2024Review
- Neoadjuvant Therapies Do Not Reduce Epidermal Growth Factor Receptor (EGFR) Expression or EGFR-Targeted Fluorescence in a Murine Model of Soft-Tissue Sarcomas.Molecular imaging and biology · 2024Article
- Metabolic targeting of cancer associated fibroblasts overcomes T-cell exclusion and chemoresistance in soft-tissue sarcomas.Nature communications · 2024Article
- Single-Stage Free Flap Reconstruction Following Extremity Sarcoma Resection: a Regional Cancer Center Experience.Indian journal of surgical oncology · 2024Article
- Prediction of soft tissue sarcoma grading using intratumoral habitats and a peritumoral radiomics nomogram: a multi-center preliminary study.Frontiers in oncology · 2024Article
- Preoperative sequential chemotherapy and hypofractionated radiotherapy combined with comprehensive surgical resection for high-risk soft tissue sarcomas: a retrospective study.Frontiers in oncology · 2024Article
- Limb Amputations in Cancer: Modern Perspectives, Outcomes, and Alternatives.Current oncology reports · 2023Review
- Survival nomograms for patients with retroperitoneal soft tissue sarcoma based on the SEER database and an external cohort.Journal of cancer research and clinical oncology · 2023Article
- Prediction of histopathologic grades of myxofibrosarcoma with radiomics based on magnetic resonance imaging.Journal of cancer research and clinical oncology · 2023Article
- Effectiveness of tumor‑treating fields to reduce the proliferation and migration of liposarcoma cell lines.Experimental and therapeutic medicine · 2023Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Soft tissue sarcomas are a rare and multifaceted group of solid tumours. Neoadjuvant chemotherapy is increasingly used to limit loss of function after wide surgical excision with the ultimate aim of improving patient survival. Recently, advances in the identification of effective treatment strategies and improvements in patient risk stratification have been reached. A randomized trial demonstrated that neoadjuvant epirubicin and ifosfamide improves survival of patients affected by five high-risk soft tissue sarcoma histologies of trunk and extremities, including undifferentiated pleomorphic sarcoma, myxoid liposarcoma, synovial sarcoma, malignant peripheral nerve sheath tumours, and leiomyosarcoma. Selection of patients for these treatments is expected to be improved by the eighth edition of the American Joint Committee on Cancer (AJCC) TNM staging system, as it tailors T-stage categories on primary tumour site and considers a prognostic nomogram for retroperitoneal sarcoma, which also includes soft tissue sarcoma histology and other patient and tumour features not directly included in the TNM staging. Within this framework, this article will present neoadjuvant treatment strategies for high-risk soft tissue sarcoma, emphasizing the most recent advances and discussing the need for further research to improve the effectiveness of neoadjuvant treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.